Participated · Equity · Jul 2026

Integral provides Forward Deployed Privacy Services that embed privacy experts directly into customer data pipelines to perform entity-preserving remediation and continuous privacy risk assessment. Its methodology is grounded in peer-reviewed statistical disclosure limitation research and was initially validated in healthcare, life sciences, and health data marketplaces. Integral produces defensibility artifacts such as Expert Determinations under HIPAA or signed defensibility opinions tailored to context, enabling enterprises and data originators to commercialize or share sensitive datasets. The company supports AI labs, data platforms, vertical AI builders, and enterprises operating in regulated environments. Following a $25 million financing, Integral plans to expand its privacy engineering and statistical methodology teams, invest in linkage and continuous assessment infrastructure, and broaden go-to-market efforts across the real-world data economy.

Participated · Series A · Dec 2023

Cytonus Therapeutics is developing a proprietary Cargocyte™ Drug Delivery Platform—engineered, synthetic cell-like delivery vehicles designed to carry multiple therapeutic payloads into hard-to-reach tissues. The company has built a pipeline of proprietary immunotherapeutic products targeting cancers, infectious diseases, inflammatory diseases, and cognitive disorders. Cargocytes are described as programmable, off-the-shelf delivery drones that can selectively, potently, and controllably deliver well-validated therapies. Cytonus will use the funds from its recent financing to continue development of this portfolio and advance payload delivery to metastatic tumors and the central nervous system. The company is led by CEO Remo Moomiaie-Qajar, MD, with Chief Scientific Innovator Richard Klemke, PhD, and executive chairman Christopher Thorne, JD-MBA. In conjunction with the financing Cytonus expanded its board and scientific advisors, including additions of Jaeyeol (Jae) An, PhD, and John C. Bell, PhD.

Participated · Seed · Aug 2023

BeFake is an AI-augmented social network from Alias Technologies that combines push-notification driven front-and-back photo posts with generative-AI image transformation via in-app presets or custom prompts. The app runs a Stable Diffusion pipeline with a custom denoising loop and proprietary components tuned for social photos, applying changes typically in under 30 seconds (often under 10), and users spend on average at least 10 minutes per session designing creations. Launched on the App Store and Google Play this month, the product supports sharing to friends, a discovery feed, and toggling between original and AI versions. BeFake generates revenue via subscriptions that pay for compute time (priced $2.99/week, $9.99/month, or $99.99/year) and offers a daily 20-minute free window via push notifications. The company is a 12-person, remotely distributed team founded as Alias Technologies in 2021 by Kristen Garcia Dumont and Tracy Lane, former Machine Zone executives. Founders say they will leverage gaming-derived approaches to rapid iteration and community building as the product moat and to adapt features to user tastes.

Participated · Seed · Aug 2023

Alias Technology develops social media applications driven by generative media and multi-modal AI, headquartered in San Francisco, CA. Its flagship product, BeFake, is an AI-driven, zero-pressure social app that lets users give photos an 'AI lift' via style prompts, curated locations, or custom text prompts. BeFake launched only weeks before the article and quickly began ranking in the App Store's Top Free charts in the United States, the United Kingdom, and France. The company intends to use the new capital to expand operations and accelerate development efforts. Founded by Kristen Garcia Dumont with COO Tracy Lane, Alias is focused on growing its mobile user base following early App Store traction.

Participated · Series A · Jul 2023

Smartlens’ flagship product, miLens, is the world’s first electronics-free soft contact lens capable of continuous intraocular pressure (IOP) measurement. The microfluidic lens pairs with the firm’s AI-powered smartphone imaging platform to capture real-time pressure data and deliver predictive analytics for glaucoma and ocular-hypertension patients. The company is running a multi-site U.S. pivotal trial and has advanced regulatory preparation, manufacturing scale-up, and clinical validation. Market demand appears strong: a Market Scope survey of 166 ophthalmic practitioners showed 96.2 % intend to adopt miLens once available. After securing FDA clearance, Smartlens plans an expedited commercial launch and expects its platform to enable earlier, data-driven interventions that could slow disease progression for the 180 million people affected by glaucoma and ocular hypertension worldwide. The recent $5.2 million bridge financing provides the capital needed to complete the clearance process and prepare for market entry.